NCT02800252

Brief Summary

Therefore, the aim of this study is to investigate the effectiveness of daily supplementation of omega-3 polyunsaturated fatty acids and low-dose aspirin as adjunct therapy to one-stage full-mouth periodontal ultrasonic debridement for the treatment of chronic periodontitis in type 2 diabetic patients through a superiority randomized clinical trial.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
75

participants targeted

Target at P25-P50 for not_applicable diabetes-mellitus

Timeline
Completed

Started Jun 2016

Typical duration for not_applicable diabetes-mellitus

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2016

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

June 10, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 15, 2016

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

November 23, 2016

Status Verified

November 1, 2016

Enrollment Period

2.5 years

First QC Date

June 10, 2016

Last Update Submit

November 22, 2016

Conditions

Keywords

fatty acidsaspirindiabetes mellituschronic periodontitisperiodontal debridement

Outcome Measures

Primary Outcomes (1)

  • Periodontal pockets with mean probing depth (PD) ≥5mm

    Baseline, 90 days, 180 days

Secondary Outcomes (5)

  • Probing depth (mm)

    Baseline, 90 days, 180 days

  • Clinical attachment level (mm)

    Baseline, 90 days, 180 days

  • Gingival recession (mm)

    Baseline, 90 days, 180 days

  • Bleeding on probing (%)

    Baseline, 90 days, 180 days

  • Plaque index (%)

    Baseline, 90 days, 180 days

Other Outcomes (1)

  • Glycated hemoglobin

    Baseline, 180 days

Study Arms (3)

Control Group

PLACEBO COMPARATOR

Full-mouth periodontal debridement and placebo

Drug: Placebo

Test 1

ACTIVE COMPARATOR

Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy

Drug: 3g omega-3 plus 100mg aspirin daily for 60 days

Test 2

ACTIVE COMPARATOR

omega-3 plus aspirin before periodontal therapy

Drug: omega-3 plus aspirin before periodontal therapy

Interventions

One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention

Control Group

Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy

Also known as: omega-3 polyunsaturated fatty acids, acetylsalicylic acid
Test 1

Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy

Also known as: omega-3 polyunsaturated fatty acids, acetylsalicylic acid
Test 2

Eligibility Criteria

Age35 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • a) Age ≥35 b) diagnosis of type 2 DM for ≥5 years c) DM treatment with oral hypoglycemic agents or insulin supplementation and diet d) glycated hemoglobin (HbA1c) levels from 6.5% to 11% e) at least 15 teeth (excluding third molars and teeth indicated for extraction) f) moderate to severe generalized chronic periodontitis (Armitage, 1999) g) agree and sign the formal consent to participate in the study after receiving an explanation of risks and benefits from an individual who is not a member of the study (Resolution number 196 - October, 1996, and Ethics and Code of Professional Conduct in Dentistry - CFO179/93).

You may not qualify if:

  • a) medical conditions that required prophylactic antimicrobial coverage b) scaling and root planing in the previous 6 months c) antimicrobial therapies in the previous 6 months d) anti-inflammatory therapies in the previous 6 months e) systemic conditions, other than DM, that could affect the progression of chronic periodontitis f) current use of medication that could interfere with periodontal response to treatment g) pregnancy or lactation h) smoking

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UNESP

São José dos Campos, São Paulo, 12245-000, Brazil

RECRUITING

Related Publications (3)

  • El-Sharkawy H, Aboelsaad N, Eliwa M, Darweesh M, Alshahat M, Kantarci A, Hasturk H, Van Dyke TE. Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 Fatty acids and low-dose aspirin. J Periodontol. 2010 Nov;81(11):1635-43. doi: 10.1902/jop.2010.090628. Epub 2010 Jun 23.

  • Castro Dos Santos N, Mangussi A, Ribeiro T, Silva RNB, Santamaria MP, Feres M, VAN Dyke T, Lorena AC. Factors influencing the response to periodontal therapy in patients with diabetes: post hoc analysis of a randomized clinical trial using machine learning. J Appl Oral Sci. 2025 Jul 25;33:e20250211. doi: 10.1590/1678-7757-2025-0211. eCollection 2025.

  • Dos Santos NC, Araujo CF, Andere NMRB, Miguel MMV, Westphal MRA, Van Dyke T, Santamaria MP. Omega-3 Fatty Acids and Low-Dose Aspirin in the Treatment of Periodontitis and Metabolic Syndrome: Case Report. J Int Acad Periodontol. 2020 Oct 1;22(4):223-230.

MeSH Terms

Conditions

Diabetes MellitusChronic Periodontitis

Interventions

Docosahexaenoic AcidsAspirin

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesPeriodontitisPeriodontal DiseasesMouth DiseasesStomatognathic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Fatty Acids, Omega-3Dietary Fats, UnsaturatedDietary FatsFatsLipidsFatty Acids, UnsaturatedFatty AcidsFish OilsOilsSalicylatesHydroxybenzoatesPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Officials

  • Mauro P Santamaria, PhD

    UPECLIN HC FM Botucatu Unesp

    STUDY DIRECTOR

Central Study Contacts

Mauro P Santamaria, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
DDS, MS

Study Record Dates

First Submitted

June 10, 2016

First Posted

June 15, 2016

Study Start

June 1, 2016

Primary Completion

December 1, 2018

Study Completion

December 1, 2018

Last Updated

November 23, 2016

Record last verified: 2016-11

Locations